Quick Takeaways
- TCG Crossover GP II, LLC filed SCHEDULE 13G/A for Dianthus Therapeutics, Inc. Common Stock, par value $0.001 per share (DNTH).
- Disclosed ownership: 4.7%.
- Date of event: 31 Mar 2025.
TCG Crossover GP II, LLC - 31 Mar 2025 SCHEDULE 13G/A Report for Dianthus Therapeutics, Inc. Common Stock, par value $0.001 per share (DNTH)
- Filing Manager
- TCG Crossover GP II, LLC
- Reporting Manager
- TCG Crossover GP II, LLC
- Symbol
- DNTH
- Shares outstanding
- 31,949,447 shares
- Disclosed Ownership
- 1,501,624 shares
- Ownership
- 4.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 16:34:05 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"TCG Crossover GP II, LLC disclosed 4.7% ownership in Dianthus Therapeutics, Inc. Common Stock, par value $0.001 per share (DNTH) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 16:34.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 4.7% | 1,501,624 | 0 | 1,501,624 | /s/ Craig Skaling | Authorized Signatory | |
| TCG Crossover Fund II, L.P. | 4.7% | 1,501,624 | 0 | 1,501,624 | /s/ Craig Skaling | Authorized Signatory | |
| Chen Yu | 4.7% | 1,501,624 | 0 | 1,501,624 | /s/ Craig Skaling | By POA as Attorney-in-Fact |